Drug Profile
Research programme: immunotherapeutic antibodies - GlaxoSmithKline/InNexus
Latest Information Update: 25 May 2007
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; InNexus Biotechnology
- Class Antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Small cell lung cancer
Most Recent Events
- 07 Nov 2005 Preclinical trials in Small cell lung cancer in USA (unspecified route)
- 17 Sep 2003 Preclinical trials in Cancer in USA (unspecified route)